Clinical Trials Browser

INDUSTRY × Octreotide × Clear all

Gastro-enteropancreatic neuroendocrine tumor

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

288 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Phase 3 Completed

231 enrolled 16 charts 2 FDA

EndocrineNET

Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Phase 2 Completed

43 enrolled 12 charts

EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Phase 2 Terminated

62 enrolled 25 charts

Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT00332969 2017-03-31

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Phase 2 Completed

25 enrolled

Thoracic

Disease, Neoplasms, Thymoma

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

20 enrolled

CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00171886 2017-02-24

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Phase 4 Completed

20 enrolled

Acromegaly

NCT00241020 2016-04-12

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Phase 3 Completed

270 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00412061 2014-11-21

RADIANT-2

Phase 3 Completed

429 enrolled 13 charts

Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT00006269 2012-05-25

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Phase 3 Terminated

89 enrolled

Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT00332696 2011-09-23

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Phase 2 Completed

64 enrolled 17 charts

Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

NCT00050635 2009-11-19

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Phase 4 Completed

150 enrolled

Gastrointestinal

Diarrhea, Neoplasms, Colorectal Neoplasms

Clinical Trials

NETTER-2

ACTION-1

NETTER-1

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

RADIANT-2

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea